Workflow
华康医疗(301235) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥229,705,391.58, a decrease of 4.37% compared to ¥240,206,327.57 in the same period last year[5] - The net profit attributable to shareholders decreased by 85.28% to -¥32,071,670.93 from -¥17,309,522.74 year-on-year[5] - The net profit after deducting non-recurring gains and losses fell by 48.16% to -¥33,396,511.35 compared to -¥22,541,585.51 in the previous year[5] - Basic and diluted earnings per share decreased by 87.50% to -¥0.3 from -¥0.16 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 229,705,391.58, a decrease of 4.2% from CNY 240,206,327.57 in the same period last year[20] - Net loss for Q1 2024 was CNY 32,071,670.93, worsening from a net loss of CNY 17,309,522.74 in Q1 2023[22] - Basic and diluted earnings per share for Q1 2024 were both CNY -0.3, compared to CNY -0.16 in the previous year[22] Cash Flow and Assets - The operating cash flow net amount improved by 27.07%, reaching -¥150,043,637.68, compared to -¥205,749,592.42 in the same period last year[5] - The net cash flow from operating activities for Q1 2024 was -150,043,637.68 CNY, compared to -205,749,592.42 CNY in Q1 2023, showing an improvement of approximately 27%[25] - Total cash inflow from operating activities was 289,291,817.13 CNY, while cash outflow was 439,335,454.81 CNY, resulting in a net cash outflow of 150,043,637.68 CNY[25] - The ending cash and cash equivalents balance for Q1 2024 was 126,526,729.46 CNY, down from 429,125,286.77 CNY in Q1 2023, indicating a decrease of about 70%[26] - Cash and cash equivalents decreased from CNY 267,939,052.33 to CNY 206,540,180.12, a reduction of about 22.9%[18] - Total current assets decreased to CNY 2,009,578,720.32 from CNY 2,114,224,400.12, a decline of approximately 4.9%[18] - Total assets at the end of the reporting period were ¥2,801,209,875.26, a decrease of 3.09% from ¥2,890,469,587.02 at the end of the previous year[5] - Total assets decreased from CNY 2,890,469,587.02 to CNY 2,801,209,875.26, a decline of about 3.1%[18] Liabilities and Equity - Total liabilities decreased to CNY 1,074,587,320.77 from CNY 1,136,553,310.20 year-over-year[20] - Total equity attributable to shareholders decreased to CNY 1,726,622,554.49 from CNY 1,753,916,276.82 in the previous year[20] Operational Changes and Costs - The increase in operating costs was attributed to significant personnel growth and the opening of a new office building, which improved brand image but raised operational expenses[8] - The company is implementing comprehensive budgeting, process reforms, and personnel qualification assessments to enhance efficiency and reduce costs[8] - Total operating costs increased slightly to CNY 267,765,573.69, compared to CNY 267,516,174.95 in Q1 2023[20] - Research and development expenses for Q1 2024 were CNY 16,462,194.83, down from CNY 23,300,468.90 in Q1 2023, indicating a 29.3% reduction[20] - Sales expenses increased to CNY 39,120,819.56 from CNY 33,931,560.78, reflecting a 15.5% rise year-over-year[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,309[10] - The company has a total of 55,676,500 restricted shares, with 1,056,000 shares released from restriction during the period[15] - The company’s major shareholder, Tan Pingtao, holds 46,708,990 shares, which remain restricted until July 28, 2025[15] - The company’s employee stock ownership platform, Wuhan Kanghui Investment Management Center, holds 4,815,360 restricted shares, also set to be released on July 28, 2025[15] Accounts Receivable and Inventory - Accounts receivable decreased from CNY 1,371,620,009.09 to CNY 1,311,674,699.46, a decrease of approximately 4.4%[18] - Inventory increased from CNY 274,909,613.70 to CNY 286,941,781.54, an increase of about 4.4%[18] Borrowings and Financing Activities - Short-term borrowings increased from CNY 409,545,194.19 to CNY 562,037,777.78, an increase of approximately 37.2%[18] - The company received 270,000,000.00 CNY from borrowings in Q1 2024, compared to 100,000,000.00 CNY in Q1 2023, indicating a 170% increase in cash inflow from financing activities[26] - The net cash flow from financing activities was 165,475,678.21 CNY, up from 97,149,635.24 CNY in the same period last year, reflecting a growth of approximately 70%[26]